RxDoctor Payments Data

Shatabdi Patel, MD

Interventional Pain Medicine · Boca Raton, FLNPI 1568669109

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $34,443 of the $43,098 with a category attached, or 79.9%. 23 manufacturers reported payments, led by AbbVie at 51.2% of the total. Reporting peaked in 2021 at $19,660 and has fallen 93.5% since, to $1,283 in 2025. Among interventional pain medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$43,098in general payments, 2019–2025

Across 236 payments — averaging $182.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$22K
  • Amgen$15K
  • Medtronic$3K
  • Collegium Pharmaceutical, Inc.$718
  • Boston Scientific$672
  • Nevro Corp.$262
  • plus $1K from 17 others

What the payments were for

  • Speaking & faculty fees$34,44380%
  • Travel & lodging$3,2538%
  • Food & beverage$5,40213%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,098 in reported general payments places this provider in the 90th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$145,185
Medicare patients
146
Services billed
11,742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate41$23,769
Buprenorphine48$9,192
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen319$6,969
MovantikNaloxegol Oxalate16$6,427
Morphine Sulfate ErMorphine Sulfate128$3,682
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen174$2,459
Tramadol Hcl ErTramadol Hcl27$1,647
Pregabalin81$1,111
Gabapentin109$1,046
Lubiprostone14$806
Tizanidine Hcl75$481
Diclofenac Sodium18$399
Tramadol Hcl67$249
Acetaminophen-CodeineAcetaminophen With Codeine19$192
Cyclobenzaprine Hcl30$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$718$23,76941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →